Status:
TERMINATED
Dose-adjusted EPOCH-R in MYC Positive DLBCL
Lead Sponsor:
Fudan University
Conditions:
Diffuse Large B-cell Lymphoma
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The aim of this study is to evaluate the efficacy and toxicity of dose-adjusted EPOCH-R in patients with MYC positive diffuse large B-cell lymphoma.
Detailed Description
The prognosis of MYC positive diffuse large B-cell lymphoma (DLBCL) is very poor even treated with R-CHOP regimen. Recently, dose-adjusted EPOCH-R was shown to be effective in patients with DLBCL and ...
Eligibility Criteria
Inclusion
- Previously untreated MYC positive diffuse large B-cell lymphoma
- Age range 18-70 years old
- Eastern Cooperative Oncology Group performance status 0-2
- Life expectancy of more than 3 months
- Adequate organ function
Exclusion
- Primary or secondary central nervous system involvement
- Previous serious cardiac disease
- History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix
- Pregnant or lactating women
- Serious uncontrolled diseases and intercurrent infection
Key Trial Info
Start Date :
February 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT01914718
Start Date
February 1 2013
End Date
December 1 2017
Last Update
August 20 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Cancer Hospital
Shanghai, Shanghai Municipality, China, 200032